Avanos Medical, Inc. (AVNS) — Fair Value Analysis

Base-case fair value (P50): $26.73 · Current price: $24.99 · Verdict: Fairly Valued

The Verdict on AVNS

AVANOS MEDICAL INC (AVNS) is currently Fairly Valued according to our Monte Carlo simulations. Our analysis indicates a median fair value (P50) of $26.73. With AVNS trading at $24.99, this represents an +7.0% upside to its calculated median fair value. This close alignment between the current market price and our P50 fair value estimate underpins the "Fairly Valued" verdict, suggesting that the stock's operational and financial health, categorized as average, is adequately reflected in its current market valuation.

How AVNS stacks up against peers

The average quality tier assigned to AVNS reflects a balanced operational and financial health when compared to companies within its sector. This designation implies that while AVNS demonstrates solid fundamentals, it doesn't possess extraordinary strengths that would significantly differentiate it or command a premium valuation beyond its current standing. An average quality tier helps stabilize the fair value estimate, reducing the likelihood of extreme divergences between $24.99 and our calculated $26.73. This consistent financial footing provides a reliable base for the Monte Carlo simulations, anchoring the median fair value within a reasonable range.

What this means for investors

For investors considering AVNS, the finding that it is Fairly Valued suggests a balanced risk-reward profile at the current $24.99. The +7.0% implied by our P50 fair value of $26.73 indicates that the market is largely efficient in pricing AVNS, given its average quality tier. While significant immediate upside may not be projected, the simulations do not indicate the stock is significantly overstretched. FairCurve users can explore the full range of bear and bull case scenarios to understand the complete distribution of potential outcomes for AVNS. Sign up for a free FairCurve account to see the full bear/bull distribution and track AVNS's fair value as new fundamentals are released.